ARS Pharmaceuticals (SPRY) Cash from Investing Activities (QoQ) (2020 - 2026)
ARS Pharmaceuticals (SPRY) Cash from Investing Activities (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | ARS Pharmaceuticals | 576.91 Mn | 375.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.25% |
| Dec 31, 2025 | 153.61% |
| Sep 30, 2025 | -192.61% |
| Jun 30, 2025 | 67.12% |
| Mar 31, 2025 | 128.56% |
| Dec 31, 2024 | -705.07% |
| Sep 30, 2024 | 232.99% |
| Jun 30, 2024 | -48.55% |
| Mar 31, 2024 | -132.69% |
| Dec 31, 2023 | 155.83% |
| Sep 30, 2023 | -203.72% |
| Jun 30, 2023 | 140.32% |
| Mar 31, 2023 | -88,428.57% |
| Dec 31, 2022 | -320.00% |
| Sep 30, 2022 | -36.36% |
| Jun 30, 2022 | -4.76% |
| Mar 31, 2022 | -100.05% |
| Dec 31, 2021 | 201.70% |
| Sep 30, 2021 | -5,622.57% |
| Jun 30, 2021 | -1,900.00% |